Day: October 11, 2017

The briefing on the European Orphan Diseases Market will benefit pharmaceutical companies.

The briefing on the European Orphan Diseases Market will benefit pharmaceutical companies, biopharmaceutical company developing drugs for rare diseases and the university spin-off drug developers. To witness the future is most likely greater consolidation through mergers and acquisitions among the large pharmaceutical and small biotech companies. Notes Frost & Sullivan Programme Leader Shabeer Hussain. Lack… Read more The briefing on the European Orphan Diseases Market will benefit pharmaceutical companies.